Letrobol 2.5 (Letrozole USP 2.5mg) is an oral aromatase inhibitor. It works by significantly decreasing estrogen production in the body. Primarily prescribed as a breast cancer treatment, it is also utilized off-label to stimulate ovulation.
Bortezomib 2 mg/mL is a specialized antineoplastic injection utilized as a potent proteasome inhibitor for treating multiple myeloma and mantle cell lymphoma. It is frequently administered subcutaneously (2.5 mg/mL) or intravenously (1 mg/mL) and works by disrupting normal cell protein degradation, leading to apoptosis of cancer cells.
| Strength | 2 mg/vial |
| Therapeutic Class: | Proteasome Inhibitor |
| Uses | Multiple Myeloma, Mantle Cell Lymphoma |
| Route of Administration | Intravenous (IV) |
| Formulation | Lyophilized powder for injection (or sometimes liquid) |
| Main Ingredients | Bortezomib Injection IP 2 mg |